Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

A study of rheumatologists in Ontario, Canada has shown an increasing percentage of women in rheumatology; unfortunately they have lower salaries but see fewer patients than do their older, male colleagues.

The American College of Rheumatology (ACR) has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provid

Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

RheumNow faculty reporters scoured the Posters and Presentations from virtual EULAR 2021.  Several of these are novel enough to be worthy of your consideration.  Below is the list of the six most often retweeted abstracts from Day 1.

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

The U.S.

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.

An open source, free read from the European Journal of Internal Medicine discusses how uric acid has evolved from the toxic cause of gout and nephrolithiasis and evolved, by way of science, into a pleiotropic recidivist in the evolution of obesity, diabetes, insulin resistance, renal disease, hypertension, fatty liver, and cardiovascular disease.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

In the current issue of Annals of Rheumatic Disease, Dr. Peggy Crow honors the life and career of one the great, historic rheumatologists of all time: Dr. Charles Christian. For those interested in the history of rheumatology, mentoring and leadership, this is a good read. For those interested in leading a truly good life, and being a real role model, this is a must read.